US Patent No: 6,858,580

Number of patents in Portfolio can not be more than 2000

Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

2 Status Updates

Stats

ALSO PUBLISHED AS: 20030228275
ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

A non-polydispersed mixture of conjugates in which each conjugate in the mixture comprises a drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugates. The mixture may be more effective at surviving an in vitro model of intestinal digestion than polydispersed mixtures of similar conjugates. The mixture may result in less inter-subject variability than polydispersed mixtures of similar conjugates.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
BIOCON LIMITEDELECTRONIC CITY95

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Ansari, Aslam M Montgomery Village, MD 16 94
Ekwuribe, Nnochiri N Cary, NC 77 383
Odenbaugh, Amy L Cary, NC 19 68
Price, Christopher H Chapel Hill, NC 28 157

Cited Art

Patent Info (Count) # Cites Year
 
ELI LILLY AND COMPANY (16)
4,839,341 Stabilized insulin formulations 49 1987
5,304,473 A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production 50 1991
5,457,066 Process for transforming a human insulin precursor to human insulin 36 1992
5,461,031 Monomeric insulin analog formulations 52 1994
5,504,188 Preparation of stable zinc insulin analog crystals 40 1994
5,646,242 Selective acylation of epsilon-amino groups 40 1994
5,693,609 Acylated insulin analogs 49 1994
5,747,642 Monomeric insulin analog formulations 41 1995
5,631,347 Reducing gelation of a fatty acid-acylated protein 35 1995
5,700,904 Preparation of an acylated protein powder 57 1995
5,952,297 Monomeric insulin analog formulations 39 1997
5,922,675 Acylated Insulin Analogs 55 1997
6,034,054 Stable insulin formulations 44 1998
6,268,335 Insoluble insulin compositions 34 1998
6,051,551 Method for administering acylated insulin 46 1998
6,335,316 Method for administering acylated insulin 48 2000
 
ENZON, INC. (16)
5,122,614 Active carbonates of polyalkylene oxides for modification of polypeptides 280 1990
5,312,808 Fractionation of polyalkylene oxide-conjugated hemoglobin solutions 47 1992
5,468,478 Conjugates of superoxide dismutage coupled to high molecular weight polyalkylene glycols 122 1993
5,643,575 Non-antigenic branched polymer conjugates 255 1993
5,612,460 Active carbonates of polyalkylene oxides for modification of polypeptides 132 1994
5,567,422 Azlactone activated polyalkylene oxides conjugated to biologically active nucleophiles 97 1994
5,405,877 Cyclic imide thione activated polyalkylene oxides 56 1994
5,650,388 Fractionated polyalkylene oxide-conjugated hemoglobin solutions 37 1995
5,637,749 Aryl imidate activated polyalkylene oxides 76 1995
5,738,846 Interferon polymer conjugates and process for preparing the same 75 1995
5,681,567 Method of preparing polyalkylene oxide carboxylic acids 65 1996
5,969,040 Factor IX -- polymeric conjugates 77 1996
5,902,588 Non-antigenic amine derived polymers and polymer conjugates 48 1997
6,177,087 Non-antigenic amine derived polymers and polymer conjugates 48 1998
6,113,906 Water-soluble non-antigenic polymer linkable to biologically active material 118 1998
6,042,822 Interferon polymer conjugates 43 1999
 
NOVO NORDISK A/S (13)
4,946,828 Novel insulin peptides 62 1987
5,164,366 Human insulin analogues 50 1989
5,202,415 Insulin precursors 26 1990
5,157,021 Insulin derivatives and pharmaceutical preparations containing these derivatives 29 1990
5,750,497 Acylated insulin 35 1995
5,948,751 X14-mannitol 46 1997
5,866,538 Insulin preparations containing NaCl 33 1997
5,905,140 Selective acylation method 31 1997
6,251,856 Insulin derivatives 31 1997
5,898,028 Method for producing powder formulation comprising an insulin 91 1998
6,043,214 Method for producing powder formulation comprising an insulin 34 1998
6,310,038 Pulmonary insulin crystals 42 1998
6,211,144 Stable concentrated insulin preparations for pulmonary delivery 40 1999
 
COLLAGEN AESTHETICS, INC. (8)
5,162,430 Collagen-polymer conjugates 261 1989
5,324,775 Biologically inert, biocompatible-polymer conjugates 153 1992
5,328,955 Collagen-polymer conjugates 163 1992
5,292,802 Collagen-polymer tubes for use in vascular surgery 138 1992
5,308,889 Dehydrated collagen-polymer strings 129 1992
5,413,791 Collagen-polymer conjugates 52 1994
5,523,348 Method of preparing collagen-polymer conjugates 36 1994
5,446,091 Collagen-polymer conjugates containing an ether linkage 44 1995
 
ASTRA AKTIEBOLAG (5)
5,658,878 Therapeutic preparation for inhalation 55 1995
5,747,445 Therapeutic preparation for inhalation 75 1996
6,004,574 Powder formulations containing melezitose as a diluent 40 1996
5,952,008 Processes for preparing compositions for inhalation 84 1997
6,165,976 Therapeutic preparation for inhalation 37 1998
 
ASTRAZENECA AB (3)
5,506,203 Systemic administration of a therapeutic preparation 123 1994
5,518,998 Therapeutic preparation for inhalation 118 1994
6,306,440 Therapeutic preparation for inhalation 35 1997
 
BIOCON LIMITED (3)
5,681,811 Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same 91 1995
6,191,105 Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin 48 1997
6,309,633 Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same 90 1999
 
ALZA CORPORATION (2)
4,684,524 Rate controlled dispenser for administering beneficial agent 80 1985
4,717,566 Dosage system and method of using same 73 1986
 
ATHENA NEUROSCIENCES, INC. (2)
5,444,041 Convertible microemulsion formulations 85 1992
5,707,648 Transparent liquid for encapsulated drug delivery 73 1995
 
CHIRON CORPORATION (2)
4,917,888 Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation 125 1987
5,089,261 Preparation of a polymer/interleukin-2 conjugate 76 1989
 
CORTECS (UK) LIMITED (2)
5,942,248 Pharmaceutical composition containing a low detergent effect bile salt and an active compound that undergoes biliary excretion and/or enterohepatic recycling 40 1995
5,968,549 Solubilisation aids 27 1997
 
DIGESTIVE CARE INC. (2)
5,415,872 Compositions of gastric acid-resistant microspheres containing salts of bile acids 35 1993
5,405,621 Compositions of gastric acid-resistant microspheres containing buffered bile acids 31 1993
 
GENENTECH, INC. (2)
5,597,797 Method for treatment or prevention of obesity 77 1993
6,057,292 Method for inhibiting growth hormone action 65 1998
 
LAI VENTURES, INC. (2)
5,359,030 Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same 109 1993
5,438,040 Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same 81 1994
 
QUIXOTE CORPORATION (2)
4,849,405 Oral insulin and a method of making the same 43 1986
4,963,526 Oral insulin and a method of making the same 43 1988
 
TAKEDA CHEMICAL INDUSTRIES, LTD. (2)
4,229,438 Nonapeptides 45 1979
4,277,394 Tetrapeptidehydrazide derivatives 34 1979
 
THE ROCKEFELLER UNIVERSITY (2)
4,348,387 Method and system for the controlled release of biologically active substances to a body fluid 37 1979
4,469,681 Method and system for the controlled release of biologically active substances to a body fluid 32 1981
 
AAIPHARMA SERVICES CORP. (1)
5,206,219 Oral compositions of proteinaceous medicaments 127 1991
 
AMERICAN HOME PRODUCTS CORPORATION (1)
4,253,998 Peptides related to somatostatin 32 1979
 
ARCO CHEMICAL TECHNOLOGY, L.P. (1)
5,714,639 Double metal cyanide catalysts and methods for making them 31 1997
 
ASTRA AKTLEBOLAG (1)
5,830,853 Systemic administration of a therapeutic preparation 106 1996
 
AUTOIMMUNE, INC. (1)
5,763,396 Method of treating or preventing type 1 diabetes by oral administration of insulin 36 1995
 
BASF AKTIENGESELLSCHAFT (1)
5,099,074 Process for the preparation of polyether glycols 26 1990
 
BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (1)
5,866,584 Therapeutic process for the treatment of the pathologies of type II diabetes 21 1995
 
CADBURY ADAMS USA LLC (1)
4,797,288 Novel drug delivery system 101 1985
 
CALIFORNIA BIOTECHNOLOGY INC. (1)
4,994,439 Transmembrane formulations for drug administration 104 1989
 
COLLAGEN CORPORATION (1)
5,550,188 Polymer conjugates ophthalmic devices comprising collagen-polymer conjugates 54 1995
 
COMPETITIVE TECHNOLOGIES, INC. (1)
5,606,038 Amphiphilic polyene macrolide antibiotic compounds 29 1995
 
DEBIO RECHERCHE PHARMACEUTIQUE S.A. (1)
5,286,637 Biologically active drug polymer derivatives and method for preparing same 86 1993
 
DEUTSCHES WOLLFORSCHUNGSINSTITUT AN DER RWTH AACHEN VELTMANPLATZ 8 (1)
6,063,761 Hepatoselective pharmaceutical actives 33 1998
 
DURKEE INDUSTRIAL FOODS CORP. (1)
4,698,264 Particulate composition and process for making same 75 1985
 
EUZON, INC. (1)
5,981,709 .alpha.-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same 39 1997
 
GLOBALFOUNDRIES INC. (1)
6,025,235 Short channel transistor having resistive gate extensions 26 1998
 
HADASSAH MEDICAL ORGANIZATION KIRYAT HADASSAH (1)
4,579,730 Pharmaceutical compositions containing insulin 58 1984
 
HAMPSHIRE CHEMICAL CORP. (1)
5,843,866 Pesticidal compositions comprising solutions of polyurea and/or polyurethane 14 1996
 
HANIL SYNTHETIC FIBER CO., LTD. (1)
5,962,267 Proinsulin derivative and process for producing human insulin 35 1996
 
HEALTH RESEARCH, INC. (1)
4,622,392 Thiophospholipid conjugates of antitumor agents 52 1984
 
HISAMITSU PHARMACEUTICAL CO., INC. (1)
5,889,153 Protein or polypeptide, method for producing the same and intermediate compound therefor 18 1997
 
HOECHST AKTIENGESELLSCHAFT (1)
4,935,246 Process for the coating of granules 99 1988
 
HOFFMANN-LA ROCHE INC. (1)
5,849,860 Polyethylene-protein conjugates 77 1995
 
KABUSHIKI KAISHA UENO SEIYAKU OYO KENKYUJO (1)
4,410,547 Sorbic acid-containing powder or granules 33 1981
 
KING'S COLLEGE (1)
5,854,208 Hepatoselective pharmaceutical actives 35 1996
 
KING'S COLLEGE LONDON OF THE STRAND (1)
6,342,225 Pharmaceutical active conjugates 36 2000
 
KYOTO YAKUHIN KOGYO KABUSHIKI KAISHA (1)
4,338,306 Adjuvant for promoting absorption of pharmacologically active substances through the rectum 41 1980
 
L'OREAL (1)
4,772,471 Aqueous dispersions of lipid spheres and compositions containing the same 95 1979
 
LEJUS MEDICAL AKTIEBOLAG (1)
4,840,799 Process for preparing rapidly disintegrating granulates 82 1987
 
LIPOCINE INC. (1)
6,248,363 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions 271 1999
 
LIPOSOME TECHNOLOGY, INC. (1)
5,013,556 Liposomes with enhanced circulation time 452 1989
 
MERCK SHARP & DOHME CORP. (1)
5,985,263 Substantially pure histidine-linked protein polymer conjugates 65 1997
 
MICROBIOLOGICAL RESEARCH AUTHORITY (1)
4,957,910 Method and composition for the treatment and prevention of viral infections 33 1988
 
NEKTAR THERAPEUTICS (1)
5,932,462 Multiarmed, monofunctional, polymer for coupling to molecules and surfaces 312 1995
 
NEW YORK BLOOD CENTER, INC. (1)
4,554,101 Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity 252 1983
 
NGK SPARK PLUG CO., LTD. (1)
4,585,745 Dielectric ceramic composition for high frequency purposes 9 1984
 
NOVOZYMES A/S (1)
5,856,451 Method for reducing respiratory allergenicity 53 1997
 
NURTURE BIOTECH INC. A DE CORP. (1)
5,055,300 Time release protein 99 1989
 
ORBON CORPORATION (1)
5,283,236 Systemic delivery of polypeptides through the eye 31 1992
 
POLYMASC PHARMACEUTICALS PLC (1)
5,349,052 Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor 70 1993
 
PROVALIS UK LIMITED (1)
6,258,377 Hydrophobic preparations containing medium chain monoglycerides 47 1998
 
SANOFI (1)
5,298,410 Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life 54 1993
 
SCHERING CORPORATION (1)
4,472,382 Treatment method 90 1983
 
SCIOS INC. (1)
5,545,618 GLP-1 analogs useful for diabetes treatment 156 1993
 
SECRETTARY, DEPARTMENT OF BIOTECHNOLOGY, GOVERNMENT OF INDIA, THE (1)
5,874,111 Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles 62 1997
 
SENJU PHARMACEUTICAL CO., LTD. (1)
5,055,304 Stabilized pharmaceutical composition and method of producing same 40 1989
 
STERLING WINTHROP, INC. (1)
5,529,915 Lyophilized polyethylene oxide modified protein and polypeptide complexes with cyclodextrin 86 1995
 
SUPERNUS PHARMACEUTICALS, INC (1)
5,824,638 Oral insulin delivery 52 1995
 
SUPRATEK PHARMA INC. (1)
6,093,391 Peptide copolymer compositions 60 1998
 
SYNGENTA LIMITED (1)
5,320,840 Continuous release pharmaceutical compositions 46 1991
 
SYNTHETIC BLOOD CORPORATION (1)
4,963,367 Drug delivery compositions and methods 221 1987
 
TELIK, INC. (1)
5,830,918 Nonpeptide insulin receptor agonists 33 1997
 
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (1)
5,093,198 Adjuvant-enhanced sustained release composition and method for making 42 1989
 
THE PROCTER & GAMBLE COMPANY (1)
4,223,163 Process for making ethoxylated fatty alcohols with narrow polyethoxy chain distribution 47 1976
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1)
4,801,575 Chimeric peptides for neuropeptide delivery through the blood-brain barrier 142 1986
 
THERATECH, INC. (1)
5,766,620 Buccal delivery of glucagon-like insulinotropic peptides 68 1995
 
TRANSCELL TECHNOLOGIES, INC. (1)
5,693,769 Glycosylated steroid derivatives for transport across biological membranes and process for making and using same 36 1994
 
UNIVERSITY OF SOUTHERN CALIFORNIA (1)
5,907,030 Method and compositions for lipidization of hydrophilic molecules 26 1995
 
UNIVERSITY OF UTAH (1)
6,323,311 Synthesis of insulin derivatives 34 1999
 
VAXCINE LIMITED (1)
5,853,748 Pharmaceutical compositions 51 1997
 
WATSON LABORATORIES, INC. (1)
4,744,976 Erodible matrix for sustained release bioactive composition 52 1986
 
WEST PHARMACEUTICAL SERVICES DRUG DELIVERY & CLINICAL RESEARCH CENTRE LIMITED (1)
6,200,602 Composition for enhanced uptake of polar drugs from the colon 56 1998
 
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (1)
6,011,008 Conjugates of biologically active substances 45 1998
 
OTHER [CHECK PATENT PROFILE FOR ASSIGNMENT INFORMATION] (2)
5,428,128 Site specific synthesis of conjugated peptides 57 1994
6,506,730 Nasal transmucosal delivery of peptide conjugated with biocompatible polymers 28 2000

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
BIOCON LIMITED (7)
7,166,571 Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same 2 2003
7,601,688 Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus 1 2003
6,930,090 Methods of activating a receptor using amphiphilic drug-oligomer conjugates 5 2003
7,662,773 Natriuretic compounds, conjugates, and uses thereof 0 2003
7,084,114 Mixtures of insulin drug-oligomer comprising polyalkylene glycol 7 2004
7,635,675 Micro-particle fatty acid salt solid dosage formulations for therapeutic agents 0 2004
8,329,958 Combinatorial synthesis of PEG oligomer libraries 0 2005
 
NEKTAR THERAPEUTICS (6)
7,786,133 Chemically modified small molecules 2 2004
7,642,323 Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation 0 2004
8,173,666 Oligomer-opioid agonist conjugates 1 2009
8,349,307 Polymer conjugates of opioid antagonists 0 2009
8,067,431 Chemically modified small molecules 1 2010
8,034,825 Chemically modified small molecules 1 2010
 
ELITE LABORATORIES INC. (2)
8,182,836 Abuse-resistant oral dosage forms and method of use thereof 0 2009
8,425,933 Abuse-resistant oral dosage forms and method of use thereof 0 2009
 
PALATIN TECHNOLOGIES, INC. (2)
7,795,221 Linear natriuretic peptide constructs 0 2007
7,622,440 Cyclic natriuretic peptide constructs 0 2007
 
INSTITUT FRANCAIS DU PETROLE (1)
7,605,123 Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof 1 2005
 
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (1)
7,741,431 Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof 0 2006
 
OTHER [CHECK PATENT PROFILE FOR ASSIGNMENT INFORMATION] (1)
8,440,687 Oligomer-opioid agonist conjugates 0 2012

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 22, 2016
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00